Key Highlights
- BriaCell Therapeutics announced FDA clearance of the IND application for Bria-PROS+.
- Bria-PROS+ is a novel personalized off-the-shelf immunotherapy candidate.
- The clearance facilitates initiation of a Phase 1/2a trial targeting prostate cancer patients.
- The program builds on foundational work funded by a $2 million National Cancer Institute grant.
BriaCell Therapeutics (NASDAQ: BCTX) announced that the FDA has cleared the IND application for Bria-PROS+, its novel personalized off-the-shelf immunotherapy candidate.
What Happened
This regulatory green light facilitates the initiation of a Phase 1/2a clinical trial targeting prostate cancer patients, building upon foundational work previously funded by a $2 million grant from the National Cancer Institute.
Market Reaction
The disclosed information does not include stock price or trading data for BriaCell Therapeutics following the IND clearance.
Outlook
Initiation of the Phase 1/2a trial targeting prostate cancer patients represents the next disclosed milestone for the Bria-PROS+ program.
What did the FDA clear for BriaCell Therapeutics?
The IND application for Bria-PROS+, a personalized off-the-shelf immunotherapy candidate.
What trial does this clearance enable?
A Phase 1/2a clinical trial targeting prostate cancer patients.
What prior funding supported this program?
A $2 million grant from the National Cancer Institute.






Please wait processing your request...